Loading
BCMA is the plasma-cell antigen behind the myeloma bispecifics and CAR-T cells. None of their labels requires a BCMA test; expression is near-universal, and loss through BCMA gene deletion is a documented escape route.
Teclistamab, elranatamab and linvoseltamab (BCMA x CD3 bispecifics), idecabtagene vicleucel and ciltacabtagene autoleucel (BCMA CAR-T) and belantamab mafodotin (BCMA ADC) are labelled for relapsed or refractory multiple myeloma by prior lines of therapy, with BCMA named in the mechanism of action only. Biallelic TNFRSF17 loss and extracellular-domain mutations after BCMA-directed therapy are reported in the literature and motivate GPRC5D- and FcRH5-directed alternatives.
In plain words · BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.
No BCMA test is needed before a BCMA bispecific or CAR-T; the antigen is assumed. If myeloma returns after one BCMA-directed treatment, your team may test whether BCMA is still present before choosing another, or move to a drug aimed at GPRC5D.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“TECVAYLI is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager”
TECVAYLI prescribing information (DailyMed)No approval uses this readout as a threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares Antigen escape (antigen loss, lineage switch) and the tags biomarker, surface-antigen.